Cardurion Pharmaceuticals
Cardurion is a next-generation cardiovascular company dedicated to addressing unmet needs in heart disease through innovative therapeutics. Founded by physician-scientists, it focuses on groundbreaking clinical programs targeting heart failure and other cardiovascular diseases, leveraging world-class expertise in cardiovascular signaling pathways to develop novel treatments and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Cardurion Pharmaceuticals
Boston, Massachusetts, United States, North America
Patents
Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-12006319-B2
View DetailsProcess for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11999741-B2
View DetailsSubstituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
US-11795172-B2
View DetailsProcess for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11370795-B2
View Details
Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-12006319-B2
View DetailsProcess for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11999741-B2
View DetailsSubstituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
US-11795172-B2
View DetailsProcess for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11370795-B2
View DetailsProducts
CRD-2015
A novel, potent, orally active, and highly selective ATP-competitive CaMKII inhibitor developed for the treatment of heart failure and cardiovascular diseases.
CRD-750
An investigational oral PDE9 inhibitor candidate for the treatment of heart failure (HFpEF and HFrEF).
CRD-740
An investigational oral PDE9 inhibitor candidate for the treatment of heart failure (HFrEF).
CRD-PDE9i
An investigational oral PDE9 inhibitor candidate designed to enhance natriuretic peptide signaling by preventing the degradation of cGMP, aiming to provide a foundational new treatment for both HFrEF and HFpEF types of heart failure.
CRD-2959
A novel, potent, and highly selective CaMKII inhibitor candidate designed for evaluation and treatment in cardiovascular diseases and heart failure models.
CRD-4730
An investigational CaMKII inhibitor drug candidate for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
CRD-2015
A novel, potent, orally active, and highly selective ATP-competitive CaMKII inhibitor developed for the treatment of heart failure and cardiovascular diseases.
CRD-750
An investigational oral PDE9 inhibitor candidate for the treatment of heart failure (HFpEF and HFrEF).
CRD-740
An investigational oral PDE9 inhibitor candidate for the treatment of heart failure (HFrEF).
CRD-PDE9i
An investigational oral PDE9 inhibitor candidate designed to enhance natriuretic peptide signaling by preventing the degradation of cGMP, aiming to provide a foundational new treatment for both HFrEF and HFpEF types of heart failure.
CRD-2959
A novel, potent, and highly selective CaMKII inhibitor candidate designed for evaluation and treatment in cardiovascular diseases and heart failure models.
CRD-4730
An investigational CaMKII inhibitor drug candidate for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
News & Updates
Cardurion announced a private investment of up to $300 million from Polaris Partners, supporting its growth and pipeline development in cardiovascular therapeutics.
Marcia Moore joins Cardurion with over 30 years of pharmaceutical and biotech leadership experience to support pipeline advancement.
The company has commenced dosing patients in a large-scale trial to evaluate CRD-740 for heart failure treatment.
FDA accepted the IND for CRD-733, and a Phase 1 trial has been initiated to evaluate safety and pharmacodynamics.
Cardurion announced a private investment of up to $300 million from Polaris Partners, supporting its growth and pipeline development in cardiovascular therapeutics.
Marcia Moore joins Cardurion with over 30 years of pharmaceutical and biotech leadership experience to support pipeline advancement.
The company has commenced dosing patients in a large-scale trial to evaluate CRD-740 for heart failure treatment.
FDA accepted the IND for CRD-733, and a Phase 1 trial has been initiated to evaluate safety and pharmacodynamics.